Amends existing law to provide that alkaloids found in or derived from Mitragyna speciosa shall be a Schedule I controlled substance.

LEGISLATURE OF THE STATE OF IDAHO
Sixty-eighth Legislature Second Regular Session - 2026
IN THE HOUSE OF REPRESENTATIVES
HOUSE BILL NO. 830
BY STATE AFFAIRS COMMITTEE
AN ACT	1
RELATING TO UNIFORM CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO	2
CODE, TO PROVIDE THAT ALKALOIDS FOUND IN OR DERIVED FROM MITRAGYNA	3
SPECIOSA SHALL BE A SCHEDULE I CONTROLLED SUBSTANCE; AND DECLARING AN	4
EMERGENCY AND PROVIDING AN EFFECTIVE DATE.	5
Be It Enacted by the Legislature of the State of Idaho:	6
SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby	7
amended to read as follows:	8
37-2705. SCHEDULE I. (a) The controlled substances listed in this sec-	9
tion are included in schedule I.	10
(b) Any of the following opiates, including their isomers, esters,	11
ethers, salts, and salts of isomers, esters, and ethers, unless specifically	12
excepted, whenever the existence of these isomers, esters, ethers and salts	13
is possible within the specific chemical designation:	14
(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip-	15
eridinyl]-N-phenylacetamide);	16
(2) Acetylmethadol;	17
(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylac-	18
etamide);	19
(4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacry-	20
lamide);	21
(5) Allylprodine;	22
(6) Alphacetylmethadol (except levo-alphacetylmethadol also known as	23
levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);	24
(7) Alphameprodine;	25
(8) Alphamethadol;	26
(9) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidi-	27
n-4-yl)-N-phenylbutanamide);	28
(10) Alpha-methylfentanyl;	29
(11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-	30
piperidinyl]-N-phenylpropanamide);	31
(12) Benzethidine;	32
(13) Betacetylmethadol;	33
(14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperid-	34
inyl]-N-phenylpropanamide);	35
(15) Beta-hydroxythiofentanyl;	36
(16) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-	37
methyl-4-piperidinyl)-N-phenylpropanamide);	38
(17) Betameprodine;	39
(18) Betamethadol;	40
(19) Beta-methyl fentanyl;	41
(20) Beta'-phenyl fentanyl;	42

-- 1 of 10 --

2
(21) Betaprodine;	1
(22) Brorphine (1-(1-(1-(4-Bromophenyl)ethyl)piperidin-4-yl)-1,3-	2
dihydro-2H-benzo[D]imidazol-2-one);	3
(23) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1hbenzimida-	4
zol-1-yl)-N,N-diethylethan-1-amine);	5
(24) Clonitazene;	6
(25) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenyl-	7
but-2-enamide);	8
(26) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcy-	9
clopentanecarboxamide);	10
(27) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcy-	11
clopropanecarboxamide);	12
(28) Dextromoramide;	13
(29) Diampromide;	14
(30) Diethylthiambutene;	15
(31) Difenoxin;	16
(32) Dimenoxadol;	17
(33) Dimepheptanol;	18
(34) 2',5'-Dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperi-	19
din-4-yl)-N-phenylpropionamide);	20
(35) Dimethylthiambutene;	21
(36) Dioxaphetyl butyrate;	22
(37) Dipipanone;	23
(38) Ethylmethylthiambutene;	24
(39) Etodesnitazene; Etazene (2-(2-(4-ethoxybenzyl)-1hbenzimida-	25
zol-1-yl)-N,N-diethylethan-1-amine);	26
(40) Etonitazene;	27
(41) Etoxeridine;	28
(42) Fentanyl-related substances. "Fentanyl-related substances"	29
means any substance not otherwise listed and for which no exemption or	30
approval is in effect under section 505 of the federal food, drug, and	31
cosmetic act, 21 U.S.C. 355, and that is structurally related to fen-	32
tanyl by one (1) or more of the following modifications:	33
i. Replacement of the phenyl portion of the phenethyl group by any	34
monocycle, whether or not further substituted in or on the monocy-	35
cle;	36
ii. Substitution in or on the phenethyl group with alkyl, alkenyl,	37
alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;	38
iii. Substitution in or on the piperidine ring with alkyl,	39
alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino,	40
or nitro groups;	41
iv. Replacement of the aniline ring with any aromatic monocycle,	42
whether or not further substituted in or on the aromatic monocy-	43
cle; and/or	44
v. Replacement of the N-propionyl group by another acyl group;	45
(43) Fentanyl carabamate;	46
(44) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1h-ben-	47
zimidazol-1-yl)ethan-1-amine);	48
(45) 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-	49
phenethylpiperidin-4-yl)isobutyramide);	50

-- 2 of 10 --

3
(46) 2'-fluoro ortho-fluorofentanyl;	1
(47) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfu-	2
ran-2-carboxamide);	3
(48) 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfu-	4
ran-3-carboxamide);	5
(49) Furethidine;	6
(50) Hydroxypethidine;	7
(51) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	8
phenylisobutyramide);	9
(52) Isovalery fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-	10
phenylbutanimide);	11
(53) Isotonitazene (N,N-diethyl-2-(2-(4isopropoxybenzyl)-5-ni-	12
tro-1h-benzimidazol-1-yl)ethan-1-amine);	13
(54) Ketobemidone;	14
(55) Levomoramide;	15
(56) Levophenacylmorphan;	16
(57) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperi-	17
din-4-yl)isobutyramide);	18
(58) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-	19
phenethylpiperidin-4-yl)isobutyramide);	20
(59) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-	21
yl)-N-phenylacetamide);	22
(60) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piper-	23
azin-1-yl)butan-1-one);	24
(61) 4'-methyl acetyl fentanyl;	25
(62) 3-Methylfentanyl;	26
(63) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-pip-	27
eridinyl]-N-phenylpropanamide);	28
(64) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1h-benzim-	29
idazol-1-yl)ethan-1-amine);	30
(65) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-	31
1hbenzimidazol-1-yl)ethan-1-amine);	32
(66) Morpheridine;	33
(67) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);	34
(68) MT-45 (1-cyclohexyl-4- (1,2-diphenylethyl)piperazine);	35
(69) N-(4-chlorophenyl)-N-(1-phenethylpiperdin-4-yl)Isobutyramide	36
(para-chloroisobutyrl fentanyl);	37
(70) Noracymethadol;	38
(71) Norlevorphanol;	39
(72) Normethadone;	40
(73) Norpipanone;	41
(74) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1-(2-	42
(pyrrolidin-1-yl)ethyl)1hbenzimidazole);	43
(75) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethyl-	44
piperidin-4-yl)acetamide);	45
(76) Ortho-fluoroacryl fentanyl;	46
(77) Ortho-fluorobutyrl fentanyl;	47
(78) Ortho-fluorofentanyl;	48
(79) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-	49
phenethylpiperidin-4-yl)furan-2-carboxamide);	50

-- 3 of 10 --

4
(80) Ortho-fluoroisobutyryl fentanyl;	1
(81) Ortho-methyl acetylfentanyl;	2
(82) Ortho-methyl methoxyacetyl fentanyl;	3
(83) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-	4
phenethylpiperidin-4-yl) isobutyramide);	5
(84) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-	6
phenethylpiperidin-4-yl) butyramide);	7
(85) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-	8
piperidinyl] propanamide);	9
(86) Para-fluoro furanyl fentanyl;	10
(87) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-	11
phenethylpiperidin-4-yl) butyramide);	12
(88) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-	13
phenethylpiperidin-4-yl)furan-2-carboxamide);	14
(89) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-	15
phenylpiperidin-4-yl)cyclopropanecarboxamide);	16
(90) Para-methylfentanyl;	17
(91) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);	18
(92) Phenadoxone;	19
(93) Phenampromide;	20
(94) Phenomorphan;	21
(95) Phenoperidine;	22
(96) Phenyl fentanyl;	23
(97) Piritramide;	24
(98) Proheptazine;	25
(99) Properidine;	26
(100) Propiram;	27
(101) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxyben-	28
zyl)-1h-benzimidazol-1-yl)ethan-1-amine);	29
(102) Racemoramide;	30
(103) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidine-4-yl)-N-	31
phenyltetrahydrofuran-2-carboxamide);	32
(104) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-	33
propanamide);	34
(105) Tilidine;	35
(106) Trimeperidine;	36
(107) u-47700 (3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-	37
methylbenzamide);	38
(108) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyl-	39
pentanamide);	40
(109) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piper-	41
azin-1-yl]-1-phenylpropan-2-ol).	42
(c) Any of the following opium derivatives, their salts, isomers and	43
salts of isomers, unless specifically excepted, whenever the existence of	44
these salts, isomers and salts of isomers is possible within the specific	45
chemical designation:	46
(1) Acetorphine;	47
(2) Acetyldihydrocodeine;	48
(3) Benzylmorphine;	49
(4) Codeine methylbromide;	50

-- 4 of 10 --

5
(5) Codeine-N-Oxide;	1
(6) Cyprenorphine;	2
(7) Desomorphine;	3
(8) Dihydromorphine;	4
(9) Drotebanol;	5
(10) Etorphine (except hydrochloride salt);	6
(11) Heroin;	7
(12) Hydromorphinol;	8
(13) Methyldesorphine;	9
(14) Methyldihydromorphine;	10
(15) Morphine methylbromide;	11
(16) Morphine methylsulfonate;	12
(17) Morphine-N-Oxide;	13
(18) Myrophine;	14
(19) Nicocodeine;	15
(20) Nicomorphine;	16
(21) Normorphine;	17
(22) Pholcodine;	18
(23) Thebacon.	19
(d) Hallucinogenic substances. Any material, compound, mixture or	20
preparation that contains any quantity of the following hallucinogenic	21
substances, their salts, isomers and salts of isomers, unless specifically	22
excepted, whenever the existence of these salts, isomers, and salts of iso-	23
mers is possible within the specific chemical designation (for purposes of	24
this subsection only, the term "isomer" includes the optical, position and	25
geometric isomers):	26
(1) Dimethoxyphenethylamine, or any compound not specifically	27
excepted or listed in another schedule that can be formed from	28
dimethoxyphenethylamine by replacement of one (1) or more hydrogen	29
atoms with another atom(s), functional group(s) or substructure(s)	30
including, but not limited to, compounds such as DOB, DOC, 2C-B,	31
25B-NBOMe;	32
(2) Methoxyamphetamine or any compound not specifically excepted or	33
listed in another schedule that can be formed from methoxyamphetamine	34
by replacement of one (1) or more hydrogen atoms with another atom(s),	35
functional group(s) or substructure(s) including, but not limited to,	36
compounds such as PMA and DOM;	37
(3) 5-methoxy-3,4-methylenedioxy-amphetamine;	38
(4) 5-methoxy-N,N-diisopropyltryptamine;	39
(5) Amphetamine or methamphetamine with a halogen substitution on the	40
benzyl ring, including compounds such as fluorinated amphetamine and	41
fluorinated methamphetamine;	42
(6) 3,4-methylenedioxy amphetamine;	43
(7) 3,4-methylenedioxymethamphetamine (MDMA);	44
(8) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-et-	45
hyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-et-	46
hyl MDA, MDE, MDEA);	47
(9) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hyd-	48
roxy-alpha-methyl-3,4(methylenedioxy) phenethylamine, and N-hyd-	49
roxy MDA);	50

-- 5 of 10 --

6
(10) 3,4,5-trimethoxy amphetamine;	1
(11) 5-methoxy-N,N-dimethyltryptamine (also known as 5-methoxy-3-2[2-	2
(dimethylamino)ethyl]indole and 5-MeO-DMT);	3
(12) Alpha-ethyltryptamine (some other names: etryptamine, 3-(2-am-	4
inobutyl) indole);	5
(13) Alpha-methyltryptamine;	6
(14) Bufotenine;	7
(15) Diethyltryptamine (DET);	8
(16) Dimethyltryptamine (DMT);	9
(17) Ibogaine;	10
(18) Lysergic acid diethylamide;	11
(19) Marihuana;	12
(20) Mescaline;	13
(21) Methoxetamine;	14
(22) Parahexyl;	15
(23) Peyote;	16
(24) N-ethyl-3-piperidyl benzilate;	17
(25) N-methyl-3-piperidyl benzilate;	18
(26) Para-methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-	19
methylpropan-2-amine;	20
(27) Psilocybin;	21
(28) Psilocyn;	22
(29) Tetrahydrocannabinols or synthetic equivalents of the substances	23
contained in the plant, or in the resinous extractives of Cannabis, sp.	24
and/or synthetic substances, derivatives, and their isomers with simi-	25
lar chemical structure such as the following:	26
i. Tetrahydrocannabinols, except for the permitted amount of	27
tetrahydrocannabinol found in industrial hemp, or nabiximols in a	28
drug product approved by the United States food and drug adminis-	29
tration:	30
a. ∆ 1 cis or trans tetrahydrocannabinol, and their opti-	31
cal isomers, excluding dronabinol in sesame oil and encapsu-	32
lated in either a soft gelatin capsule or in an oral solution	33
in a drug product approved by the U.S. Food and Drug Adminis-	34
tration.	35
b. ∆ 6 cis or trans tetrahydrocannabinol, and their optical	36
isomers.	37
c. ∆ 3,4 cis or trans tetrahydrocannabinol, and its optical	38
isomers. (Since nomenclature of these substances is not in-	39
ternationally standardized, compounds of these structures,	40
regardless of numerical designation of atomic positions are	41
covered.)	42
d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methy-	43
loctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-	44
1-o1)], also known as 6aR-trans-3-(1,1-dimethylhep-	45
tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-	46
dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric	47
isomers (HU211 or dexanabinol).	48
ii. The following synthetic drugs:	49

-- 6 of 10 --

7
a. Any compound structurally derived from (1H-indole-3-	1
yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-in-	2
dole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methane, or	3
(1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl), methyl	4
or dimethyl butanoate, amino-methyl (or dimethyl)-1-oxobu-	5
tan-2-yl) carboxamide by substitution at the nitrogen atoms	6
of the indole ring or carboxamide to any extent, whether or	7
not further substituted in or on the indole ring to any ex-	8
tent, whether or not substituted to any extent in or on the	9
cycloalkyl, cycloalkenyl, aryl ring(s) (substitution in the	10
ring may include, but is not limited to, heteroatoms such as	11
nitrogen, sulfur and oxygen).	12
b. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluo-	13
ropentyl)-1 H-indazole-3-carboxamide (5F-AB-PINACA).	14
c. 1-(1.3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one	15
(N-ethylpentylone, ephylone).	16
d. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-inda-	17
zole-3-carboxamide (4-cn-cumyl-BUTINACA).	18
e. 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-	19
one (Cumyl PeGACLONE).	20
f. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3carboxam-	21
ido)-3,3-dimethylbutanoate * (5F-EDMB-PINACA).	22
g. Ethyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-	23
3,3-dimethylbutanoate (5F-EDMB-PICA).	24
h. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3tetram-	25
ethylcyclopropyl)methanone ( FUB-144).	26
i. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-inda-	27
zole-3-carboxamide (5f-cumyl-pinaca; SGT-25).	28
j. (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1	29
H-pyrrolo[2.3-B]pyridine-3-carboxamide(5fcumyl-P7AICA).	30
k. FUB-AMB, MMB- FUBINACA (Methyl 2-(1-(4-fluoroben-	31
zyl)-1H-indazole-3-carboxamido)-3-methylbutanoate.	32
l. MMB-FUBICA (Methyl 2-(1-(4-Fluorobenzyl)-1H-Indole-3-	33
carboxamido)-3-methyl butanoate).	34
m. Methyl 3,3-dimethyl-2-((1-(pent-4-en-1-yl)-1H-inda-	35
zol-3-yl)formamido)butanoate (MDMB-4EN-PINACA).	36
n. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-	37
ido)-3-methylbutanoate (MMB-CHMICA, AMB-CHMICA).	38
o. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-	39
ido)-3,3-dimethylbutanoate (MDMB-CHMICA).	40
p. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxam-	41
ido-3,3-dimethylbutanoate (MDMB-FUBINACA).	42
q. Methyl 2-[[1-(4-Fluorobutyl)Indole-3-Carbonyl]Amino]-	43
3,3-Dimethyl-Butanoate (4F-MDMB-BUTICA).	44
r. Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxam-	45
ido)-3,3-dimethylbutanoate (5F-MDMBPICA).	46
s. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-	47
ido)-3,3-dimethylbutanoate (5F-ADB, 5FMDMB-PINACA).	48
t. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-	49
ido)-3-methylbutanoate (5FAMB).	50

-- 7 of 10 --

8
u. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-	1
Indazole-3-carboxamide (ADB-BUTINACA).	2
v. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluo-	3
robenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA).	4
w. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-	5
en-1-yl)-1H-indazole-3-carboxamide (ADB-4EN-PINACA).	6
x. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-	7
carboxamide (FUB-AKB48; FUB-APINACA).	8
y. N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-	9
carboxamide (5F-APINACA, 5F-AKB48).	10
z. N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(Cyclohexyl-	11
methyl)-1H-indazole-3-carboxamide (AB-CHMINACA).	12
aa. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-car-	13
boxylate (NM2201; CBL2201).	14
bb. Any compound structurally derived from 3-(1-naph-	15
thoyl)pyrrole by substitution at the nitrogen atom of the	16
pyrrole ring to any extent, whether or not further sub-	17
stituted in the pyrrole ring to any extent, whether or not	18
substituted in the naphthyl ring to any extent.	19
cc. Any compound structurally derived from 1-(1-naphthyl-	20
methyl)indene by substitution at the 3-position of the in-	21
dene ring to any extent, whether or not further substituted	22
in the indene ring to any extent, whether or not substituted	23
in the naphthyl ring to any extent.	24
dd. Any compound structurally derived from 3-pheny-	25
lacetylindole by substitution at the nitrogen atom of the	26
indole ring to any extent, whether or not further substi-	27
tuted in the indole ring to any extent, whether or not sub-	28
stituted in the phenyl ring to any extent.	29
ee. Any compound structurally derived from 2-(3-hydroxy-	30
cyclohexyl)phenol by substitution at the 5-position of the	31
phenolic ring to any extent, whether or not substituted in	32
the cyclohexyl ring to any extent.	33
ff. Any compound structurally derived from 3-(benzoyl)in-	34
dole structure with substitution at the nitrogen atom of	35
the indole ring to any extent, whether or not further sub-	36
stituted in the indole ring to any extent and whether or not	37
substituted in the phenyl ring to any extent.	38
gg. [2,3-dihydro-5-methyl-3-(4-morpholinyl-	39
methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-	40
napthalenylmethanone (WIN-55,212-2).	41
hh. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-	42
243).	43
ii. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-	44
5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahy-	45
drophenanthridin-1-yl]acetate (CP 50,5561).	46
(30) Ethylamine analog of phencyclidine: N-ethyl-1-phenylcy-	47
clohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcy-	48
clohexyl) ethylamine, cyclohexamine, PCE;	49

-- 8 of 10 --

9
(31) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl) -	1
pyrrolidine, PCPy, PHP;	2
(32) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-	3
piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;	4
(33) Thiofuranyl fentanyl;	5
(34) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name: TCPy;	6
(35) Spores or mycelium capable of producing mushrooms that contain	7
psilocybin or psilocin.	8
(e) Unless specifically excepted or unless listed in another schedule,	9
any material, compound, mixture or preparation which contains any quantity	10
of the following substances having a depressant effect on the central ner-	11
vous system, including its salts, isomers, and salts of isomers whenever the	12
existence of such salts, isomers, and salts of isomers is possible within the	13
specific chemical designation:	14
(1) Clonazolam;	15
(2) Diclazepam;	16
(3) Gamma hydroxybutyric acid (some other names include GHB; gam-	17
ma-hydroxybutyrate, 4-hydroxybutyrate; 4-hyroxybutanoic acid; sod-	18
ium oxybate; sodium oxybutyrate);	19
(4) Etizolam;	20
(5) Flualprazolam;	21
(6) Flubromazolam;	22
(7) Flunitrazepam (also known as R2, Rohypnol);	23
(8) Mecloqualone;	24
(9) Methaqualone.	25
(f) Stimulants. Unless specifically excepted or unless listed in an-	26
other schedule, any material, compound, mixture, or preparation which con-	27
tains any quantity of the following substances having a stimulant effect on	28
the central nervous system, including its salts, isomers, and salts of iso-	29
mers:	30
(1) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-	31
yl)amino]heptanoic acid);	32
(2) Aminorex (some other names: aminoxaphen, 2-amino-5-phenyl-2-ox-	33
azoline, or 4,5-dihydro-5-phenyl-2-oxazolamine), 4,4'-dimethylam-	34
inorex (4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazo-	35
lamine) or (4,5-dihydro-5-phenyl-2-oxazolamine);	36
(3) Cathinone (some other names: 2-amino-1-phenol-1-propanone, alp-	37
ha-aminopropiophenone, 2-aminopropiophenone and norephedrone);	38
(4) Substituted cathinones. Any compound, except bupropion or com-	39
pounds listed under a different schedule, structurally derived from	40
2-aminopropan-1-one by substitution at the 1-position with either	41
phenyl, naphthyl or thiophene ring systems, whether or not the compound	42
is further modified in any of the following ways:	43
i. By substitution in the ring system to any extent with alkyl,	44
alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide sub-	45
stituents, whether or not further substituted in the ring system	46
by one (1) or more other univalent substituents;	47
ii. By substitution at the 3-position with an acyclic alkyl sub-	48
stituent;	49

-- 9 of 10 --

10
iii. By substitution at the 2-amino nitrogen atom with alkyl,	1
dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the	2
2-amino nitrogen atom in a cyclic structure.	3
(5) Alpha-pyrrolidinoheptaphenone* (PV8);	4
(6) Alpha-pyrrolidinohexanophenone* (A-PHP);	5
(7) 4-chloro-alpha-pyrrolidinovalerophenone* (4chloro-a-pvp);	6
(8) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one);	7
(9) Fenethylline;	8
(10) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadia-	9
zol-3-ium-5-yl)carbamimidate);	10
(11) Methcathinone (some other names: 2-(methyl-amino)-propioph-	11
enone, alpha-(methylamino)-propiophenone, N-methylcathinone, AL-	12
464, AL-422, AL-463 and UR1423);	13
(12) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine);	14
(13) (+/-)cis-4-methylaminorex [(+/-)cis-4,5-dihydro-4-meth-	15
yl-5-phenyl-2-oxazolamine];	16
(14) 4-methyl-alpha-ethylaminopentiophenone* (4-MEAP);	17
(15) 4'-methyl-alpha-pyrrolidinohexiophenone* (MPHP);	18
(16) 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-MMC);	19
(17) 4-methyl-1-phenyl-2-(pyrrolidine-1-yl)pent-1-one) (ALPHA-	20
PIHP);	21
(18) N-benzylpiperazine (also known as: BZP, 1-benzylpiperazine);	22
(19) N-ethylamphetamine;	23
(20) N-ethylhexedrone*;	24
(21) N,N-dimethylamphetamine (also known as: N,N-alpha-trimethyl-	25
benzeneethanamine).	26
(g) Unless specifically excepted or unless listed in another schedule,	27
any alkaloids found in or derived from Mitragyna speciosa, including syn-	28
thetic alkaloids, homologs, analogs, isomers, esters, ethers, salts, and	29
salts of isomers, esters, and ethers, when the existence of the isomers, es-	30
ters, ethers, and salts is possible within the specific chemical designa-	31
tion.	32
SECTION 2. An emergency existing therefor, which emergency is hereby	33
declared to exist, this act shall be in full force and effect on and after	34
July 1, 2026.	35

-- 10 of 10 --